SEC Form 3 · accession 0001193125-26-382432
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roberto Wandenkolk Vieira
Officer — President, Oncology
Period of report
Sep 1, 2026
Accepted (ET)
Sep 3, 2026 · 8:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 4,068 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2 | $21.63 | holding | — | — | — | — | Feb 1, 2034 | Common Stock | 200,000 | — | D |
| Stock option (right to buy)F3 | $60.58 | holding | — | — | — | — | Feb 28, 2035 | Common Stock | 140,000 | — | D |
| Stock option (right to buy)F4 | $35.70 | holding | — | — | — | — | Feb 27, 2036 | Common Stock | 140,000 | — | D |
Explanation of responses
- F1Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards vested or will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F2There were originally 400,000 shares subject to the stock option and an aggregate of 200,000 shares have been previously exercised. The shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.
- F3Exercisable ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date.
- F4Exercisable ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date.
Remarks
Exhibit 24 - Power of Attorney